ADMA Biologics, Inc. (ADMA)

NASDAQ: ADMA · USD

$11.3

+0.10 (+0.9%)· Recorded snapshot

Market cap	2.5B
Revenue (ttm)	512.3M
Net income (ttm)	169M
EPS (ttm)	$0.70
Shares out	224M
P/E (trailing)	16.1x
P/E (forward)	13.7x
Volume	1,980,018
Beta	0.69

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 512.3M
Net income (ttm): 169M
EPS (ttm): $0.70
P/E (trailing): 16.1x
P/E (forward): 13.7x
Market cap: 2.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13.7

P25 n/aP50 n/aP75 n/a

Trailing P/E16.1

P25 n/aP50 n/aP75 n/a

ROE41.9

P25 n/aP50 n/aP75 n/a

ROIC36.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ADMA indicators

Market & fundamental data

Available fields

252

Groups with data

Currency

USD

Showing 252 of 252 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001368514
Company name	ADMA Biologics, Inc.
Country	United States
Country code	US
CUSIP number	000899104
Earnings date	2026-11-04
Earnings time	amc
Employees	647
Employees change	-38
Employees growth	-5.55%
Enterprise value	$2.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2004
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US0008991046
Last 10-K release date	2026-02-25
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$11.27
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ADMA
U.S. state	New Jersey
Website	https://www.admabiologics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	15.8x
Average P/E ratio (3Y)	30.86x
Earnings yield	6.21%
EV/Earnings	15.25x
EV/EBIT	11.9x
EV/EBITDA	11.49x
EV/FCF	22.12x
EV/Sales	5.03x
FCF / EV yield	4.52%
FCF yield	4.64%
Forward EV/Sales	4.43x
Forward P/E	13.74x
Forward P/S	4.31x
Graham number	5.34264
Graham upside	-52.3%
P/(FCF - SBC) ratio	26.81x
P/(OCF - SBC) ratio	22.04x
P/B ratio	6.17x
P/E ratio	16.09x
P/FCF ratio	21.54x
P/OCF ratio	18.35x
P/S ratio	4.9x
Price / tangible book value	6.21x
Price/EBITDA ratio	11.19x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	42.26%
EBITDA margin	43.76%
Effective tax rate	21.95%
FCF margin	22.74%
Gross margin	64.71%
Operating margin	42.26%
Pretax margin	42.26%
Profit margin	32.98%
Profit per employee	$261,141
Profitable quarters	10
Profitable years	2
Revenue per employee	$791,770
ROA	21.78%
ROA (5Y)	4.82%
ROCE	35.58%
ROE	41.9%
ROE (5Y)	-1.98%
ROIC	36.24%
ROIC (5Y)	8.83%
SBC / revenue	4.47%
Tax / revenue	9.28%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-17%
EPS growth (Q)	14.29%
EPS growth (QoQ)	-15.79%
EPS growth quarters	2
EPS growth years	0
FCF growth	77.08%
FCF growth (Q)	45.77%
FCF growth (QoQ)	-51.02%
Gross profit growth	31.89%
Gross profit growth (Q)	28.34%
Gross profit growth 3Y	79.79%
Net income growth	-19.13%
Net income growth (Q)	10.53%
Net income growth (QoQ)	-16.56%
Net income growth quarters	2
Net income growth years	0
OCF growth	78.23%
OCF growth (Q)	39.74%
OCF growth (QoQ)	-49.29%
Operating income growth	39.11%
Operating income growth (Q)	22.54%
Revenue growth	8.04%
Revenue growth (Q)	1.98%
Revenue growth (QoQ)	8.65%
Revenue growth 10Y	50.21%
Revenue growth 3Y	35.02%
Revenue growth 5Y	54.54%
Revenue growth quarters	1
Revenue growth years	7

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-20.3M
Depreciation and amortization	$7.7M
EBIT	$216.5M
EBITDA	$224.2M
EPS	$0.70
FCF per share	$0.52
Financing cash flow	$-76.5M
Free cash flow	$116.5M
Free cash flow minus SBC	$93.6M
Gross profit	$331.5M
Income taxes	$47.5M
Investing cash flow	$-14.5M
Net borrowing	$123.1M
Net cash flow	$45.7M
Net income	$169M
Operating cash flow minus SBC	$113.8M
Operating income	$216.5M
Revenue	$512.3M
Stock-based compensation	$22.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	10.04
Book value per share	$1.81
Debt / EBITDA	0.9
Debt / equity	0.5
Debt / FCF	1.75
Goodwill	$3.5M
Interest coverage	24.53
Long-term assets	$156M
Long-term liabilities	$200.2M
Net cash (debt)	$-67.8M
Net cash / market cap	-2.7%
Net debt / EBITDA	0.3
Net debt / equity	0.17
Net debt / FCF	0.58
Piotroski F-Score	5
Property, plant and equipment	$72.8M
Shareholders' equity	$408.2M
Tangible book value	$404.1M
Tangible book value per share	$1.79
Total assets	$684.2M
Total cash	$136M
Total debt	$203.8M
Total liabilities	$276M
WACC	7.72%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.82
Current assets	$528.2M
Current liabilities	$75.8M
Current ratio	6.97
Inventory turnover	0.84
Net working capital	$321.4M
Quick ratio	3.62
Working capital	$452.4M
Working capital turnover	1.32

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.15%
Dividend yield	0%
Shareholder yield	-1.15%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	90.79%
10Y return CAGR	6.67%
10Y total return	90.79%
150-day SMA	$9.36
1D price change	0.9%
1M price change	18.18%
1M total return	18.18%
1W price change	-1.29%
1W total return	-1.29%
1Y price change	-28.94%
1Y return CAGR	-28.96%
1Y total return	-28.94%
20-day SMA	$10.56
200-day SMA	$11.02
3M price change	30.72%
3M total return	30.72%
3Y price change	234.89%
3Y return CAGR	49.6%
3Y total return	234.89%
50-day SMA	$9.93
50-day SMA vs 200-day SMA	50under200
52-week high	$20.46
52-week high date	2025-12-12
52-week low	$7.21
52-week low date	2026-03-26
5Y price change	721.11%
5Y return CAGR	52.37%
5Y total return	721.11%
6M price change	1.42%
6M total return	1.42%
All-time high	$25.67
All-time high date	2025-04-28
All-time low	$1.01
All-time low date	2021-10-21
Average true range (ATR)	$0.36
Average volume	2.7M
Beta (1Y)	1.67
Beta (2Y)	0.83
Beta (5Y)	0.69
Change from 52-week high	-44.91%
Change from 52-week low	56.31%
Change from all-time high	-56.82%
Change from all-time low	997.52%
Change from open	2.08%
Day's gap	-1.16%
Dollar volume	$22.3M
High price	$11.28
Low price	$11.01
Monthly RSI	47.01
Open price	$11.04
Position in 52-week range	96.3%
Premarket change	-0.18%
Premarket close	$11.17
Premarket price	$11.15
Premarket volume	19.4K
Previous close	$11.17
Price vs 150-day SMA	18.4%
Price vs 20-day SMA	4.93%
Price vs 200-day SMA	0.58%
Price vs 50-day SMA	11.65%
Relative volume	0.72
RSI	63.18
Sharpe ratio	-0.43
Sharpe ratio (3Y)	0.96
Sharpe ratio (5Y)	1
Sortino ratio	-0.46
Sortino ratio (3Y)	1.63
Sortino ratio (5Y)	1.71
Volume	2M
Weekly RSI	55.1
YTD price change	-39.23%
YTD total return	-39.23%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	219.7M
Float percentage	98.07%
Shares change (QoQ)	-4.01%
Shares change (YoY)	1.15%
Shares held by insiders	1.89%
Shares held by institutions	91.78%
Shares outstanding	224M
Short % of float	9.38%
Short % of shares	9.2%
Short ratio	7 days

Deeper analysis on ADMA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ADMA report

Is a complete ADMA research report available?

No complete published report is available for ADMA Biologics, Inc. (ADMA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ADMA Biologics, Inc. (ADMA)

Price

Financial snapshot

Fair-value bridge

Latest news · ADMA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ADMA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ADMA

Frequently asked questions